New approaches to the endocrine prevention and treatment of breast cancer.
AffiliationCRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK. email@example.com
MetadataShow full item record
AbstractAll major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.
CitationNew approaches to the endocrine prevention and treatment of breast cancer. 2003, 52 Suppl 1:S39-44 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology
- The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
- Authors: Bevers TB
- Issue date: 2007 Sep
- Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
- Authors: Ganz PA, Land SR
- Issue date: 2008 Jul-Aug
- Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
- Issue date: 2006 May 8
- Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
- Authors: Dunn BK, Ryan A
- Issue date: 2009 Feb
- Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
- Authors: Dunn BK, Ford LG
- Issue date: 2007 Jun